Arch Biopartners, U of Calgary Extend Agreement

Arch Biopartners Inc ("Arch" or the "Company")(CNSX:ACH)(OTC:FOIFF) today
announced that the University of Calgary has extended the overhead agreement
with its subsidiary Arch Biotech Inc. ("AB") and has granted a similar overhead
agreement to its subsidiary Arch Cancer Therapeutics Ltd ("ACT").


Both overhead agreements are valid until July 1, 2012. 

About Arch Cancer Therapeutics 

ACT is an Alberta corporation wholly owned by Arch. ACT's objective is to
develop non-invasive diagnostic and therapeutic molecules for brain cancer
utilizing new and innovative approaches. 


About Arch Biotech

AB is an Ontario corporation wholly-owned by Arch and is focused on novel
treatments for chronic kidney and bowel diseases caused by non-infectious
inflammation.


About Arch Biopartners 

Arch Biopartners is a portfolio-based biotechnology company that is developing
early stage proprietary technology for sale to pharmaceutical and industrial
companies.


The Company's website address is: www.archbiopartners.com.

For more information on the Company, please consult the other public documents
filed on SEDAR at www.sedar.com. 


Forward-Looking Statements 

All statements, other than statements of historical fact, in this news release
are forward looking statements that involve various risks and uncertainties,
including, without limitation, statements regarding the future plans and
objectives of the Company. There can be no assurance that such statements will
prove to be accurate. Actual results and future events could differ materially
from those anticipated in such statements. These and all subsequent written and
oral forward-looking statements are based on the estimates and opinions of
management on the dates they are made and are expressly qualified in their
entirety by this notice. The Company assumes no obligation to update
forward-looking statements should circumstances or management's estimates or
opinions change.